Comprehensive investigation of matrix metalloproteinases in skin cutaneous melanoma: diagnostic, prognostic, and therapeutic insights.

Comprehensive investigation of matrix metalloproteinases in skin cutaneous melanoma: diagnostic, prognostic, and therapeutic insights.

Publication date: Jan 16, 2025

The dysregulation of matrix metalloproteinases (MMPs) in skin cutaneous melanoma (SKCM) represents a critical aspect of tumorigenesis. In this study, we investigated the diagnostic, prognostic, and therapeutic aspects of the MMPs in SKCM. Thirteen SKCM cell lines and seven normal skin cell lines were cultured under standard conditions for experimental analyses. RNA and DNA were extracted, followed by RT-qPCR to assess MMP expression and promoter methylation analysis to determine methylation levels. Functional assays, including cell proliferation, colony formation, and wound healing, were conducted post-MMP7 knockdown using siRNA in A375 cells. Databases like GEPIA2, HPA, MEXPRESS, and miRNet were employed for expression, survival, methylation, and miRNA-mRNA network analyses. We investigated the expression and promoter methylation landscape of MMPs in SKCM cell lines, revealing significant (p-value 

Open Access PDF

Concepts Keywords
A375 Biomarker
Cultured Biomarkers, Tumor
Cutaneous Biomarkers, Tumor
Metalloproteinases Cell Line, Tumor
Tumorigenesis Cell Proliferation
DNA Methylation
Female
Humans
Male
Matrix Metalloproteinases
Matrix Metalloproteinases
Melanoma
Melanoma, Cutaneous Malignant
MicroRNAs
MicroRNAs
Middle Aged
MMPs
Prognosis
Prognosis
Promoter Regions, Genetic
SKCM
Skin Neoplasms
Treatment

Semantics

Type Source Name
disease MESH melanoma
pathway KEGG Melanoma
disease MESH tumorigenesis
pathway REACTOME Methylation
drug DRUGBANK Saquinavir
disease MESH tumor
disease MESH skin cancer
drug DRUGBANK Coenzyme M
drug DRUGBANK Zinc
disease MESH inflammation
disease MESH metastasis
pathway REACTOME Immune System
drug DRUGBANK Isoxaflutole
drug DRUGBANK Marimastat
drug DRUGBANK Spinosad
pathway REACTOME Translation
disease MESH clinical relevance
drug DRUGBANK Honey
drug DRUGBANK Flunarizine
drug DRUGBANK Gold
drug DRUGBANK Water
drug DRUGBANK Urea
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Phosphate ion
drug DRUGBANK Tromethamine
disease MESH death
disease MESH pathogenesis
pathway REACTOME Apoptosis
disease MESH hypoxia
drug DRUGBANK Gentian violet cation
disease MESH mutation frequencies
disease MESH functional status
pathway KEGG Cell adhesion molecules
drug DRUGBANK Pralatrexate
drug DRUGBANK Oxygen
drug DRUGBANK Vemurafenib
drug DRUGBANK Azithromycin
disease MESH squamous carcinoma
disease MESH carcinomas
disease MESH lymphomas
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
disease MESH cervical cancer
pathway REACTOME Collagen degradation
disease MESH hepatocellular carcinoma
pathway KEGG Hepatocellular carcinoma
disease MESH oxidative stress
drug DRUGBANK Mexiletine
disease MESH recurrence
disease MESH colon cancer
drug DRUGBANK Huperzine B
drug DRUGBANK Bismuth subgallate
drug DRUGBANK L-Tyrosine
disease MESH vitiligo
pathway KEGG Ferroptosis
drug DRUGBANK Chlorine
disease MESH glioma
pathway KEGG Glioma
disease MESH oral mucositis
drug DRUGBANK Guanosine
disease MESH nasopharyngeal carcinoma
disease MESH osteosarcoma
disease MESH mucoepidermoid carcinomas
disease MESH sepsis
disease MESH acute kidney injury
disease MESH mitochondrial dysfunction
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH lung cancer
disease MESH adenocarcinoma
pathway REACTOME Reproduction
pathway REACTOME DNA methylation
disease MESH Melanoma Cutaneous Malignant

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *